Related references
Note: Only part of the references are listed.A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo
Leandro C. Cerchietti et al.
CANCER CELL (2010)
Mechanisms of Disease: Aggressive Lymphomas.
Georg Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma
J. Ruan et al.
ANNALS OF ONCOLOGY (2009)
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
Kieron Dunleavy et al.
BLOOD (2009)
Cellular Source and Amount of Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor in Tumors Determine Response to Angiogenesis Inhibitors
Barbara Sennino et al.
CANCER RESEARCH (2009)
Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma
Annina Herrmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108
Alison T. Stopeck et al.
LEUKEMIA & LYMPHOMA (2009)
TGF-β Is Required for Vascular Barrier Function, Endothelial Survival and Homeostasis of the Adult Microvasculature
Tony E. Walshe et al.
PLOS ONE (2009)
Development of a Fully Human Anti-PDGFR beta Antibody That Suppresses Growth of Human Tumor Xenografts and Enhances Antitumor Activity of an Anti-VEGFR2 Antibody
Juqun Shen et al.
NEOPLASIA (2009)
B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma
Weimin Ci et al.
CURRENT OPINION IN HEMATOLOGY (2008)
Stromal Gene Signatures in Large-B-Cell Lymphomas
G. Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting
Kristian Pietras et al.
PLOS MEDICINE (2008)
Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis
Lars Johan Nissen et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102
Barbara Sennino et al.
CANCER RESEARCH (2007)
Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma
Yasuhiko Kitadai et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphomna
Jia Ruan et al.
CLINICAL CANCER RESEARCH (2006)
Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis
Kristen N. Ganjoo et al.
LEUKEMIA & LYMPHOMA (2006)
Tumor-driven paracrine platelet-derived growth factor receptor α signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma
ML Tejada et al.
CLINICAL CANCER RESEARCH (2006)
Pericytes limit tumor cell metastasis
XJ Xian et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
State-of-the-art therapeutics: Diffuse large B-cell lymphoma
B Coiffier
JOURNAL OF CLINICAL ONCOLOGY (2005)
PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival
S Song et al.
NATURE CELL BIOLOGY (2005)
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib
AL Dewar et al.
BLOOD (2005)
Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients
Y Yonenaga et al.
ONCOLOGY (2005)
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
SS Dave et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer
NC Wolff et al.
CLINICAL CANCER RESEARCH (2004)
Tumorigenesis and the angiogenic switch
G Bergers et al.
NATURE REVIEWS CANCER (2003)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
G Bergers et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy
M Enge et al.
EMBO JOURNAL (2002)
Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug
R Capdeville et al.
NATURE REVIEWS DRUG DISCOVERY (2002)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Vascular-specific growth factors and blood vessel formation
GD Yancopoulos et al.
NATURE (2000)
Share Paper
